Manteia Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Xiamen Fujian China

Primary Industry

Healthcare IT

About

Based in Xiamen, China and established in 2017, Manteia is a medical company that provides medical systems for adaptive radiation therapy. As of 2023, the company has passed the US FDA, China NMPA Class III, European CE and Korean KFDA product registration certification. In 2023, it develops and launches MOZI-Online TPS, the first plan design system that supports multiple guided images (CBCT/CT/MR). In January 2024,it raised a series B funding for CNY 110 million. The company's main products include AccuContour (an intelligent radiotherapy image workstation), Online ART-TPS (an adaptive radiotherapy system) and ARTCheck (a real-time adaptive radiotherapy plan QA system). In addition, AccuContour provides image analysis and radiomics tools. The company's products are used in clinical treatment and other fields. Its clients are the Mayo Clinic, the National Cancer Center & Proton Center (NCC) of Korea, Seoul National University Hospital (SNUH), Peking Union Medical College Hospital, and the General Hospital of the People's Liberation Army.

Current Investors

Fosun International, DYEE Capital, Redhill Capital

Request a demo to show more

Primary Industry

Healthcare IT

Sub Industries

Healthcare IT, Medical Software

Website

www.manteiatech.com

Verticals

Artificial Intelligence, HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.